[go: up one dir, main page]

EA201690881A1 - Соединения-ингибиторы аутотаксина - Google Patents

Соединения-ингибиторы аутотаксина

Info

Publication number
EA201690881A1
EA201690881A1 EA201690881A EA201690881A EA201690881A1 EA 201690881 A1 EA201690881 A1 EA 201690881A1 EA 201690881 A EA201690881 A EA 201690881A EA 201690881 A EA201690881 A EA 201690881A EA 201690881 A1 EA201690881 A1 EA 201690881A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
autotaxin
compounds inhibitors
inhibitors
methods
Prior art date
Application number
EA201690881A
Other languages
English (en)
Other versions
EA030068B1 (ru
Inventor
Джон Говард Хатчинсон
Дэвид Лонерган
Original Assignee
Фармакеа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармакеа, Инк. filed Critical Фармакеа, Инк.
Publication of EA201690881A1 publication Critical patent/EA201690881A1/ru
Publication of EA030068B1 publication Critical patent/EA030068B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В изобретении описываются соединения, которые являются ингибиторами аутотаксина, способы получения таких соединений, фармацевтические композиции и медицинские препараты, содержащие такие соединения, а также способы применения таких соединений в лечении состояний, заболеваний или нарушений, ассоциированных с аутотаксиновой активностью.
EA201690881A 2013-11-22 2014-11-20 Соединения-ингибиторы аутотаксина EA030068B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907965P 2013-11-22 2013-11-22
US201462038121P 2014-08-15 2014-08-15
PCT/US2014/066706 WO2015077503A1 (en) 2013-11-22 2014-11-20 Autotaxin inhibitor compounds

Publications (2)

Publication Number Publication Date
EA201690881A1 true EA201690881A1 (ru) 2016-12-30
EA030068B1 EA030068B1 (ru) 2018-06-29

Family

ID=53180152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690881A EA030068B1 (ru) 2013-11-22 2014-11-20 Соединения-ингибиторы аутотаксина

Country Status (31)

Country Link
US (7) US9334261B2 (ru)
EP (2) EP3071561B1 (ru)
JP (1) JP6501367B2 (ru)
KR (2) KR102515248B1 (ru)
CN (2) CN110372671B (ru)
AU (2) AU2014352888B2 (ru)
BR (1) BR112016010220B1 (ru)
CA (1) CA2930737C (ru)
CL (1) CL2016001231A1 (ru)
CR (2) CR20160289A (ru)
CY (1) CY1124407T1 (ru)
DK (1) DK3071561T3 (ru)
EA (1) EA030068B1 (ru)
ES (1) ES2875899T3 (ru)
HR (1) HRP20210957T1 (ru)
HU (1) HUE055213T2 (ru)
IL (2) IL245383B (ru)
LT (1) LT3071561T (ru)
MX (2) MX375706B (ru)
MY (1) MY182095A (ru)
NI (1) NI201600071A (ru)
NZ (1) NZ720478A (ru)
PE (1) PE20160654A1 (ru)
PH (1) PH12016500862B1 (ru)
PL (1) PL3071561T3 (ru)
PT (1) PT3071561T (ru)
RS (1) RS62027B1 (ru)
SI (1) SI3071561T1 (ru)
SM (1) SMT202100531T1 (ru)
WO (1) WO2015077503A1 (ru)
ZA (2) ZA201603083B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186159A1 (en) 2012-06-13 2013-12-19 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
PE20150758A1 (es) 2012-09-25 2015-05-15 Hoffmann La Roche Nuevos derivados biciclicos
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
CN105764903B (zh) 2013-11-22 2018-09-18 法玛克亚公司 四环自分泌运动因子抑制剂
AU2014352888B2 (en) 2013-11-22 2019-05-09 Sabre Therapeutics Llc Autotaxin inhibitor compounds
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
ES2753549T3 (es) 2014-03-26 2020-04-13 Hoffmann La Roche Compuestos bicíclicos como inhibidores de la producción de autotaxina (ATX) y ácido lisofosfatídico (LPA)
CA2935612A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EA039684B1 (ru) * 2015-05-27 2022-02-28 Сабре Терапьютикс Ллс Ингибиторы аутотаксина и их применения
WO2017037146A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
CN115124538A (zh) 2015-09-24 2022-09-30 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
US11000142B2 (en) 2016-12-06 2021-05-11 John Joseph Girard Flexible floor mat incorporating LED lighting
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
JP7241080B2 (ja) 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
EP4519253A1 (en) * 2022-05-03 2025-03-12 Sabre Therapeutics LLC Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法
CN116396205B (zh) * 2023-04-20 2024-10-01 沈阳药科大学 一种n-芳基吲哚衍生物及其制备方法和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
KR940703981A (ko) 1992-11-10 1994-12-12 존 에이취. 롱 솔레노이드 밸브 조립체(Solenoid valve assembly)
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
WO2002028865A2 (en) 2000-10-03 2002-04-11 Lilly Icos Llc Condensed pyridoindole derivatives
BR0208790A (pt) 2001-04-11 2004-03-30 Idenix Cayman Ltd Fenilindoìs para o tratamento de hiv
PT1438289E (pt) 2001-09-27 2005-06-30 Hoffmann La Roche Derivados de indole como inibidores de cox ii
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
HRP20050181A2 (en) 2002-08-29 2006-03-31 Merck & Co. Inc. Indoles having anti-diabetic activity
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
BRPI0417858B1 (pt) 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
US7905958B2 (en) 2004-05-19 2011-03-15 Sumitomo Electric Industries, Ltd. Group III-nitride semiconductor crystal and manufacturing method thereof, and group III-nitride semiconductor device
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
WO2006050236A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
EP1962838B1 (en) 2005-12-19 2011-09-28 GlaxoSmithKline LLC Farnesoid x receptor agonists
CA2690762C (en) 2007-06-15 2016-06-14 Glenn Prestwich .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
EP2352732B1 (en) 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
SG174928A1 (en) 2009-04-02 2011-11-28 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
SG174520A1 (en) * 2009-04-02 2011-10-28 Merck Patent Gmbh Heterocyclic compounds as autotaxin inhibitors
KR20120004483A (ko) 2009-04-02 2012-01-12 메르크 파텐트 게엠베하 오토탁신 저해제
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
JP5903735B2 (ja) 2009-05-11 2016-04-13 バーグ エルエルシー エピメタボリックシフター（コエンザイムｑ１０）を使用した疾患の処置方法
US8592388B2 (en) 2009-05-20 2013-11-26 Eth Zurich Targeting MicroRNAs for metabolic disorders
WO2011002918A1 (en) 2009-06-30 2011-01-06 The University Of Memphis Research Foundation Novel diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
CN102822171B (zh) * 2010-03-26 2015-09-02 默克专利有限公司 作为自分泌运动因子抑制剂的苯并萘啶胺类
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
WO2012024620A2 (en) * 2010-08-20 2012-02-23 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US8673882B2 (en) 2011-01-20 2014-03-18 University Of Tennessee Research Foundation Inhibitors of autotaxin
EP2675458A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
WO2013186159A1 (en) 2012-06-13 2013-12-19 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
PE20150758A1 (es) 2012-09-25 2015-05-15 Hoffmann La Roche Nuevos derivados biciclicos
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
CN104968656B (zh) 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
JP2016530210A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ヘテロ環式ビニルオートタキシン阻害剤化合物
EP3049405A4 (en) * 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
JP2016536363A (ja) 2013-11-05 2016-11-24 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 節足動物を処理するための置換されたベンズアミド
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
CN105764903B (zh) 2013-11-22 2018-09-18 法玛克亚公司 四环自分泌运动因子抑制剂
AU2014352888B2 (en) 2013-11-22 2019-05-09 Sabre Therapeutics Llc Autotaxin inhibitor compounds
PL3071560T3 (pl) 2013-11-22 2018-07-31 Basf Se N-acyloiminowe związki heterocykliczne
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
EA039684B1 (ru) 2015-05-27 2022-02-28 Сабре Терапьютикс Ллс Ингибиторы аутотаксина и их применения

Also Published As

Publication number Publication date
CR20160289A (es) 2016-09-27
EA030068B1 (ru) 2018-06-29
CN110372671B (zh) 2023-02-21
AU2019213425B2 (en) 2021-01-07
ES2875899T3 (es) 2021-11-11
CN110372671A (zh) 2019-10-25
RS62027B1 (sr) 2021-07-30
CN105793253A (zh) 2016-07-20
KR102515248B1 (ko) 2023-03-29
MX375706B (es) 2025-03-06
ZA202005029B (en) 2022-02-23
ZA201603083B (en) 2022-03-30
US20160374991A1 (en) 2016-12-29
NZ720478A (en) 2022-02-25
WO2015077503A8 (en) 2015-07-16
CR20190394A (es) 2019-10-29
US11344533B2 (en) 2022-05-31
KR20160079082A (ko) 2016-07-05
US20160235713A1 (en) 2016-08-18
US20180243267A1 (en) 2018-08-30
MY182095A (en) 2021-01-18
EP3071561A4 (en) 2017-04-12
HK1226075A1 (zh) 2017-09-22
HRP20210957T1 (hr) 2021-09-17
EP3071561A1 (en) 2016-09-28
AU2014352888A1 (en) 2016-06-09
JP6501367B2 (ja) 2019-04-17
US10688081B2 (en) 2020-06-23
US11779568B2 (en) 2023-10-10
US9334261B2 (en) 2016-05-10
KR102367876B1 (ko) 2022-02-24
PT3071561T (pt) 2021-06-25
CN105793253B (zh) 2019-08-23
US9468628B2 (en) 2016-10-18
SMT202100531T1 (it) 2021-11-12
US9999615B2 (en) 2018-06-19
HUE055213T2 (hu) 2021-11-29
BR112016010220A2 (pt) 2018-05-02
JP2016537389A (ja) 2016-12-01
PH12016500862A1 (en) 2016-07-18
US20240189281A1 (en) 2024-06-13
BR112016010220B1 (pt) 2023-05-09
DK3071561T3 (da) 2021-06-21
PE20160654A1 (es) 2016-07-15
EP3878848A1 (en) 2021-09-15
CL2016001231A1 (es) 2017-01-20
SI3071561T1 (sl) 2021-11-30
PL3071561T3 (pl) 2021-11-08
EP3071561B1 (en) 2021-03-24
NI201600071A (es) 2016-09-21
KR20220027276A (ko) 2022-03-07
IL245383A0 (en) 2016-06-30
PH12016500862B1 (en) 2020-12-09
AU2014352888B2 (en) 2019-05-09
IL245383B (en) 2019-11-28
LT3071561T (lt) 2021-08-25
US12268668B2 (en) 2025-04-08
AU2019213425A1 (en) 2019-08-29
MX2016006623A (es) 2017-03-10
CY1124407T1 (el) 2022-07-22
IL270168B (en) 2022-02-01
US20200268713A1 (en) 2020-08-27
MX2020009780A (es) 2020-10-12
US20160046614A1 (en) 2016-02-18
CA2930737C (en) 2023-02-21
WO2015077503A1 (en) 2015-05-28
CA2930737A1 (en) 2015-05-28
US20220265608A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
MX389684B (es) Anticuerpos anti tigit.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201691773A1 (ru) Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PC4A Registration of transfer of a eurasian patent by assignment